The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Aug 31, 2026
Snapshot (as of Aug 31, 2026): Gilead Sciences, Inc. (GILD) pays a $3.22 annual dividend ($0.82 quarterly), yielding 2.21% at $145.68/share. Next ex-dividend date 2026-09-15. 9+ consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.21%
Annual Dividend: $3.22 per share
Payout Ratio: -125.6%
Ex-Dividend Date: 2026-09-15
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 12
Gilead Sciences, Inc. dividend reflects a global biopharmaceutical business built around treatments for HIV, liver disease, and cancer, with flagship products including Biktarvy, Trodelvy, and Veklury. GILD currently pays $3.22 per share annually, with a quarterly frequency and an upcoming ex-dividend date of September 15, 2026. The current yield stands at 2.2%. With a beta of 0.336, GILD stock moves well below the broader market, which suits income investors who prioritize low volatility over high yield.
Gilead Sciences, Inc. pays out -125.6% of earnings as dividends, a payout ratio classified as conservative (below 40%) — though the negative figure reflects a net loss period rather than an unsustainably high cash commitment. Gilead Sciences, Inc. dividend safety draws support from a product portfolio anchored in chronic-condition therapies like Biktarvy for HIV, where ongoing patient demand provides a recurring revenue base. The most significant data-supported pressure point is that negative earnings, if prolonged, could eventually constrain the company's capacity to maintain or grow the payout.
Over the past nine years, Gilead Sciences, Inc. dividend history shows a CAGR of 6.2% per year from 2016 to 2025. The per-share payment grew from $1.84 to $3.16 over that window (2026 is a partial year and excluded from the growth calculation). The smallest annual increase in the window was 2.6% in 2025, which shows growth has slowed from the 13.0% peak recorded in 2017.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +2.7% | $2.92 (2022) | $3.16 (2025) |
| 5-Year | +3.0% | $2.72 (2020) | $3.16 (2025) |
| 10-Year | +9.4% | $1.29 (2015) | $3.16 (2025) |
GILD stock fits dividend investors who want a moderate, low-volatility income stream from a biopharmaceutical company with a long-running increase streak. The yield of 2.2% falls within the moderate (2-4%) range and sits above the 5-year average of 2.05%, meaning current buyers lock in a slightly better yield than the historical norm. Growth has been real but is decelerating: 6.2% annually over nine years, down to 2.6% in the most recent full year. Nine consecutive years of increases is the gain. Slowing growth and a negative earnings base are the trade-offs.
| Payment Date | Amount per Share |
|---|---|
| 2026-09-15 | $0.8200 |
| 2026-06-15 | $0.8200 |
| 2026-03-13 | $0.8200 |
| 2025-12-15 | $0.7900 |
| 2025-09-15 | $0.7900 |
| 2025-06-13 | $0.7900 |
| 2025-03-14 | $0.7900 |
| 2024-12-13 | $0.7700 |
| 2024-09-13 | $0.7700 |
| 2024-06-14 | $0.7700 |
| Year | Total Dividends |
|---|---|
| 2026 | $2.4600 |
| 2025 | $3.1600 |
| 2024 | $3.0800 |
| 2023 | $3.0000 |
| 2022 | $2.9200 |
Project income from GILD with the GILD dividend calculator or track your full portfolio with the dividend tracker.